RET mutation and expression in small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1316-1323

  Dabir, Snehal ^a   Babakoohi, Shahab ^b   Kluge, Amy ^a   Morrow, James J ^c,d   Kresak, Adam ^d   Yang, Michael ^d   MacPherson, David ^e   Wildey, Gary ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Oncogene; RET; Small cell lung cancer; SNP; Tyrosine kinase inhibitors

Indexed keywords

MESSENGER RNA; MYC PROTEIN; PONATINIB; PROTEIN RET; VANDETANIB; RET PROTEIN, HUMAN; RNA;

AGED; ARTICLE; CANCER CELL LINE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DATA BASE; DNA EXTRACTION; ENZYME ACTIVATION; EXON; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WILD TYPE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SMALL CELL LUNG CANCER; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA;

EID: 84906269974     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000234     Document Type: Article

References (27)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366: 1385-1396.
2. D'Angelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 2010;10:1-10.
3. Nickolich M, Babakoohi S, Fu P, Dowlati A. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. Clin Lung Cancer 2014;15:207-212.
4. William WN Jr, Glisson BS. Novel strategies for the treatment of smallcell lung carcinoma. Nat Rev Clin Oncol 2011;8:611-619.
5. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-414.
6. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-1116.
7. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-1110.
8. Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 2013;98:3149-3164.
9. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173-186.
10. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-6281.
11. Futami H, Egawa S, Tsukada T, et al. A novel somatic point mutation of the RET Proto-oncogene in tumor tissues of small cell lung cancer patients. Jpn J Cancer Res 1995;86:1127-1130.
12. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
13. Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 1999;18:3919-3922.
14. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-377.
15. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381.
16. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer patients. Nature Med 2012;18:382-384.
17. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-4359.
18. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 2013;104:1396-1400.
19. Kosari F, Ida CM, Aubry M-C, et al. ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. Oncogene [published online ahead of print Sept 16, 2013].
20. Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18:3722-3730.
21. Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 2013;19:524-529.
22. Tsao AS, Liu S, Lee JJ, et al. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 2013;8:658-661.
23. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-smallcell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-626.
24. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR20. J Clin Oncol 2007;25:4278-4284.
25. Aisner J, Manola JB, Dakhil SR, Stella PJ, Sovak MA, Schiller JH. Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501). J Thorac Oncol 2013;8:1075-1083.
26. Tian W, Ding W, Kim S, et al. Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. PLoS One 2013;8:e67929.
27. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.